Stretched Valuations in Biotech Require Cautious Approach

Healthcare >> Analyst Interviews >> December 15, 2014

Stefan Quenneville is an Equity Analyst for Morningstar, covering biotechnology companies. Mr. Quenneville has more than a decade of experience in the investment industry. Before joining Morningstar in 2013, he was a Senior Analyst for Stanton Asset Management in Canada. Previously, he was Vice President of health care research for Macquarie Group Limited, a global investment bank headquartered in Australia. He has also covered health care for other leading Canadian investment banks including Orion Securities — acquired by Macquarie — and Desjardins Securities. Mr. Quenneville began his career as a Consultant for the World Bank as part of a satellite and Web-based distance education project called the African Virtual University. He has also worked as a Management Consultant serving a range of clients, including technology, media and retail companies, international organizations, and nonprofits. Mr. Quenneville holds a bachelor’s degree in biology and environmental sciences, and an MBA with a concentration in finance from McGill University. He also holds the Chartered Financial Analyst designation. Profile

TWST: To start out, can you introduce yourself by giving us a snapshot of your coverage?

Mr. Quenneville: I'm a Biotech Analyst at Morningstar. I cover a number of biotech

Join for free to read a longer excerpt or purchase this article

Stretched Valuations in Biotech Require Cautious Approach

Top Company Interviews

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS

Stretched Valuations in Biotech Require Cautious Approach

Top Company Interviews

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS

SECTOR ROUNDTABLES

MONEY MANAGER INTERVIEWS

ANALYST INTERVIEWS